Salute e Benessere

Ramsay Sante : Ramsay Santé has successfully refinanced its Senior Debt Facility

PRESS RELEASE Paris, 13 August 2024 Ramsay Santé has successfully refinanced its Senior Debt FacilityOn 13 August 2024, Ramsay Santé completed the Amend & Extend process of its €1,650m Senior Debt facility, including a €100m revolving credit facility, a €100m capex facility, and a €1,450m Term Loan B facility, proactively extending its upcoming 2026-2027 debt maturities to 2029-2031. This transaction was arranged by BNP Paribas and Crédit Agricole CIB as Global Coordinators for...
Nasdaq GlobeNewswire
13/08/2024

Intracardiac Echocardiography (ICE) Market worth $545 million by 2029 driven by…

Browse in-depth TOC on "Intracardiac Echocardiography (ICE) Market" Browse in-depth TOC on "Intracardiac Echocardiography (ICE) Market" 261 - Tables56 - Figures 297 - Pages Abbott Laboratories: Leading Provider of Intracardiac Echocardiography Technologies Abbott Laboratories (US) is a key player in intracardiac echocardiography (ICE), offering advanced solutions such as the ViewFlex Xtra ICE Catheter and the ViewMate Ultrasound Console. These technologies provide...
PR Newswire
13/08/2024

inThought Launches the Insights Framework

inThought creates a unique roadmap for each client that identifies key business objectives across multidisciplinary teams. inThought defines when, where, and how strategic insights will be obtained to address and advance those objectives. This is executed with frequent communication and transparent timelines that allow clients to focus on their own priorities knowing that inThought has them covered. With flexibility and customization to fit any client's needs, the inThought Insights Framework is…
PR Newswire
13/08/2024

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and…

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- - Received Rare Pediatric Disease Designation (RPDD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for...
Nasdaq GlobeNewswire
13/08/2024

Notice of Nexstim Plc's Half-Year Report H1 2024

Press release,Helsinki,13 August2024 at 3 PM(EEST) Noticeof NexstimPlc's Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time.The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational...
Nasdaq GlobeNewswire
13/08/2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for…

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive...
Nasdaq GlobeNewswire
13/08/2024

BioSenic S.A. : Transparency notification received from ABO Infinium Americas…

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, August 13, 2024, 1.00pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of...
Nasdaq GlobeNewswire
13/08/2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profileRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024 Next data update on IMA203 and IMA203CD8 (GEN2) to be presented at medical conferences in 2H 2024First...
Nasdaq GlobeNewswire
13/08/2024

Anti Aging Products Market to Reach $108.5 Billion, Globally, by 2033 at 6.9%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06331 Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06331 Prime determinants of growth The prime determinants of growth in the anti-aging products market include technological advancements, increasing consumer awareness, and evolving beauty trends. Innovations in skincare technology, such as the development of more effective active...
PR Newswire
13/08/2024

MolecuLight's Breakthrough Imaging Technology Promotes Health Equity in Wound…

Disproportionally poor health outcomes are near-universal for Black Americans, including wounds. Between 2013-2014, Black Americans with diabetic ulcers in rural areas faced double the risk of major leg amputation or death following hospitalization compared to their White counterparts residing in similar regionsii. "There are now technologies that can identify more Black patients with wound infections who can be treated more efficaciously to prevent infection complications including…
PR Newswire
13/08/2024

Image-Guided Radiation Therapy Market to Reach $3.3 Billion, Globally, by 2033…

Request Sample of the Report on Image-Guided Radiation Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323701 Request Sample of the Report on Image-Guided Radiation Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323701 Prime determinants of growth Image-guided radiation therapy (IGRT) is experiencing significant growth due to several key drivers such as technological advancements in imaging modalities such as...
PR Newswire
13/08/2024

Intravenous (IV) Hydration Therapy Market to Reach $4.9 Billion, Globally, by…

Request Sample of the Report on Intravenous (IV) Hydration Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323708 Request Sample of the Report on Intravenous (IV) Hydration Therapy Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/A323708 Prime determinants of growth Increasing prevalence of dehydration-related conditions, and growing health and wellness trends are the major factors that drive the growth of the...
PR Newswire
13/08/2024

Salt Medical: A New Medical Device Design Contract Manufacturer to open in…

Who is Salt Medical? Salt Medical establishes a renowned international medical device platform with an extensive global research and development (R&D) and manufacturing infrastructure. The company operates R&D and manufacturing facilities inIreland, along with raw material and precision component supply and large-scale manufacturing facilities in theUnited Statesand theAsia Pacificregion. Specialising in the production of catheters, guidewires, medical...
PR Newswire
13/08/2024

Philips and Dutch Isala Hospital renew long-term partnership focused on…

Amsterdam, The Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Isala hospital (Zwolle, The Netherlands) have renewed their long-term strategic partnership to enhance healthcare delivery through innovative and cost-effective solutions. This collaboration aims to ensure healthcare remains accessible, available, and affordable by leveraging Philips' advanced technology, data analytics, and AI. Focusing on the radiology and cardiology...
Nasdaq GlobeNewswire
13/08/2024

Regenics AS completes first tranche of a NOK 54 M private placement to initiate…

Each Unit consists of one common share in Regenics AS and one- and one-half share purchase warrants (a "Warrant"). Each Warrant will entitle Nordic Blue to purchase one common share, at a price of NOK 9 per unit, until December 31st 2024, representing an additional capital raise of 34 MNOK. Each Unit consists of one common share in Regenics AS and one- and one-half share purchase warrants (a "Warrant"). Each Warrant will entitle Nordic Blue to purchase one common share, at a…
PR Newswire
13/08/2024

Calliditas Interim Report January to June 2024

January to June 2024 (compared to January to June 2023) January toJune 2024(compared to January toJune 2023 ) Key takeaways from Q2, 2024 Key events after the reporting period Asahi Kasei Offer Outlook 2024: Updated Calliditas expects continued revenue growth: Total net sales from the Nefecon franchise, including milestones, are estimated to beUSD 165 -185 million for the year endingDecember 31, 2024. Investor Presentation Today, 13 August at2...
PR Newswire
13/08/2024

Basilea reports strong 2024 half-year results and significantly increases…

Continued success of Cresemba ®with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 million and operating profit guidance increased by 20% to CHF ~36 million Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, August 13, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Nasdaq GlobeNewswire
13/08/2024

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

First-Half Sales Performance in Line with Full-Year 2024 GuidanceTotal revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasingNet Profit of €34.0 million, including proceeds from PRV saleOperating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed...
Nasdaq GlobeNewswire
13/08/2024

Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in…

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, August 13, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of two financing agreements that provided the Company with gross funding totaling approximately CHF 69 million. Together with existing cash resources, this will support the Company's growth initiatives, repayment of maturing convertible bonds and liquidity through to the first half of 2026, at which point Santhera expects to be cash flow break-even...
Nasdaq GlobeNewswire
13/08/2024

SPECTUM DYNAMICS MEDICAL AND DEEPDENSE MEDICAL ENTER INTO A PARTNERSHIP TO…

Spectrum Dynamic's customers will benefit from DEEPDENSE's best-in-class unique AI applications with visualization and editing tools. These AI applications can be added to the portfolio of solutions that Spectrum Dynamics offers to reduce healthcare costs and improve patient care. In addition, DEEPDENSE Medical's labeling toolkit offers unique 3D labeling tools that boosts R&D of AI applications. Spectrum Dynamic's customers will benefit from DEEPDENSE's best-in-class unique AI…
PR Newswire
13/08/2024

Tecan reports financial results for the first half of 2024 and revises its…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports financial results for the first half of 2024and revises its outlook for full year 2024Financial results for the first half of 2024 – Highlights Sales of CHF 467.2 million (H1 2023: CHF 541.5 million) Sales development of -11.6% in local currencies or -13.7% in Swiss francsDecline in sales mainly due to softness in the instrument business with biopharmaceutical companies...
Nasdaq GlobeNewswire
13/08/2024

Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over…

Second Quarter 2024 Financial Highlights Second Quarter 2024 Financial Highlights Infographic -https://mma.prnewswire.com/media/2480462/Innocan_Figure_A_Infographic.jpg Management Comments Iris Bincovich, the CEO of Innocan commented: "Our LPT-CBD technology continues to make solid advancements, and we are very pleased with our progress. At the end of July, we achieved a milestone and met with the FDA to discuss our clinical plan for bringing our LPT-CBD technology to...
PR Newswire
12/08/2024

QSA Global, Inc. and Niowave, Inc. Establish Collaboration to Improve Radium…

QSA and Niowave will co-develop a scaled radium purification process to meet the ever-increasing demand for Ac-225. QSA will commence multi-year supply of purified Ra-226 to Niowave in early 2025 and extend this supply to third parties in 2026. This collaboration is expected to significantly increase the availability of high-purity Ra-226 to the radioisotope ecosystem and improve the probability that Niowave and other Ac-225 manufacturers can meet the growing demand for Ac-225. QSA and…
PR Newswire
12/08/2024

Long-Read Sequencing Market worth $3,129 million in 2029 driven by Technological…

Browse in-depth TOC on "Long-Read Sequencing Market" Browse in-depth TOC on "Long-Read Sequencing Market" 398 - Tables 60 - Figures 306 - Pages Oxford Nanopore Technologies plc: Leader in Long-Read Sequencing Solutions Oxford Nanopore Technologies plc (UK) is a prominent biotechnology company specializing in proprietary platforms for long-read sequencing. With a robust presence in over 100 countries, the company serves clinical, academic, and research communities globally...
PR Newswire
12/08/2024
Altri  Comunicati